

Sun Pharmaceutical Industries Limited,
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



March 24, 2023

National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001

Scrip Symbol: SUNPHARMA

Scrip Code: 524715

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that Sun Pharmaceutical Industries Limited (which includes its subsidiaries and/or associate companies) ("Company") has entered into an agreement to acquire 60% shareholding in Vivaldis Health And Foods Private Limited from its existing shareholders with remaining 40% shareholding to be acquired in future as per certain terms & conditions.

The particulars of the disclosure required as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are provided in **Annexure A** as enclosed herewith.

This is for your information and dissemination.

Thank You,

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Annexure A

Disclosure under sub-para (1) i.e. Acquisition(s) (including agreement to acquire) of Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
1	Name of the target entity, details in brief such as size, turnover etc.;	<p>Vivaldis Health And Foods Private Limited (“Target”), a private limited company duly incorporated under the Companies Act, 2013, having corporate identification number (‘CIN’) U24297PN2014PTC150393 and having its registered office at Office No. 803, Clover Hills Plaza, SN-27(PT) Pl, Kondhwa, Pune – 411048, Maharashtra, India.</p> <p>The Target is engaged in the business of trading, distributing, manufacturing and marketing of drugs, food supplements and over the counter products in the companion animal segment of animal healthcare industry.</p> <p>The revenue for the financial year 2021-22 was INR 29.92 crores.</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	No, the transaction is not a related party transaction and promoter / promoter group does not have any interest in the entity whose securities are being acquired.
3	Industry to which the entity being acquired belongs;	Animal healthcare industry.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Non-material investment in allied areas.
5	Brief details of any governmental or regulatory approvals required for the acquisition;	None.
6	Indicative time period for completion of the acquisition;	By the end of May 2023.

7	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration.								
8	Cost of acquisition or the price at which the shares are acquired;	INR 143.30 crores subject to customary closing adjustments for 60% (sixty percent) shareholding.								
9	Percentage of shareholding/ control acquired and/ or number of shares acquired;	60% (sixty percent) shareholding in the Target being acquired currently from Existing shareholders, with remaining 40% (forty percent) shareholding in the Target being acquired in future as per certain terms & conditions.								
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p>The Target is engaged in the business of trading, distributing, manufacturing and marketing of drugs, food supplements and over the counter products in the companion animal segment of animal healthcare industry.</p> <p>The Target was incorporated on January 31, 2014. The revenue for previous three years are as follows:</p> <table border="1" data-bbox="762 1243 1348 1433"> <thead> <tr> <th>Financial year</th> <th>Amount (INR in crores)</th> </tr> </thead> <tbody> <tr> <td>2021-22</td> <td>29.92</td> </tr> <tr> <td>2020-21</td> <td>20.54</td> </tr> <tr> <td>2019-20</td> <td>13.80</td> </tr> </tbody> </table> <p>The revenues of the Target have grown at CAGR of 47% during FY 19-20 to FY 21-22 period.</p>	Financial year	Amount (INR in crores)	2021-22	29.92	2020-21	20.54	2019-20	13.80
Financial year	Amount (INR in crores)									
2021-22	29.92									
2020-21	20.54									
2019-20	13.80									